易明医药：预计2025年净利润同比增长61.12%-122.08%

Core Viewpoint - The company expects a net profit of 74 million to 102 million yuan for the fiscal year 2025, representing a year-on-year growth of 61.12% to 122.08% [1] Group 1: Financial Performance - The company is focusing resources on the development of self-produced products, which has led to an increase in the sales volume of its core proprietary product, Miglitol tablets, thereby boosting overall profits [1] - Non-recurring gains and losses are primarily derived from government subsidies and compensation payments from the performance commitments of Bostai, with an estimated impact of 43 million yuan on the company's net profit [1]